Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well ispinesib works in treating patients with metastatic
or unresectable kidney cancer. Ispinesib may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth.